Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
Related Posts
Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]
Chauhan A, Hendifar AE, El-Haddad G, Soares HP, Herrmann K. The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate[...]
Fracol ME, Miranda RN, Tsao AS, Rodriguez MM, Nastoupil LJ, Young PA, Sherrod AE, LeBlanc DM, Hunsicker LM, Bacchi CE, Gabriel T, Myckatyn TM, Tanaka[...]